PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Practice Signal

Acute Ischemic Stroke Reperfusion: Extended-Window Thrombolytics

This review helps pharmacists understand how imaging-based patient selection and tenecteplase have widened thrombolysis eligibility and where the extended-window evidence still falls short.

Bottom Line

Imaging-based selection now extends intravenous thrombolysis to 9 hours and wake-up stroke, and tenecteplase has become an equal first-line agent to alteplase within 4.5 hours, but adding a late-window lytic on top of thrombectomy in perfusion-selected large-vessel occlusion has not improved functional outcomes.

COR 1
tenecteplase equal to alteplase <4.5h
COR 2a
extended-window thrombolysis 4.5-9h
OR 1.13
TIMELESS late-window disability, ns
NNT ~9
WAKE-UP favorable 90-day outcome

State of Play

Acute ischemic stroke (AIS) reperfusion has shifted from a strict clock-based model toward tissue-based, imaging-selected eligibility, allowing thrombolysis in wake-up and late-presenting patients. Tenecteplase has moved from an alternative to an equal first-line thrombolytic within 4.5 hours, largely on the strength of workflow advantages and noninferiority data. The central unresolved tension is whether a late-window lytic adds anything for patients already headed to endovascular thrombectomy.

🔒
Full Analysis: Subscribers Only
The complete evidence synthesis, practice recommendations, and open questions.
What Changed
How It Fits the Guidelines
Effect chart & evidence comparison
Evidence at a Glance
Practice Considerations
Open Questions
Want the full review?

Subscribe to PharmD Signal for the complete evidence synthesis and practice recommendations on every topic, plus every deep analysis we publish.

Become a Subscriber →
tenecteplase alteplase intravenous thrombolysis endovascular thrombectomy acute ischemic stroke large-vessel occlusion wake-up stroke perfusion imaging DWI-FLAIR mismatch D-dimer/fibrinogen ratio AHA/ASA ESO
🎓
Synthesized and reviewed by a licensed pharmacist
Each Practice Signal is built from our published deep analyses and checked for clinical accuracy before it goes live.
Not medical advice. PharmD Signal provides educational synthesis of published pharmacy and medical literature for practicing pharmacists. It is not a treatment recommendation for any individual patient; clinical decisions remain the responsibility of the treating clinician exercising independent professional judgment.
Thanks for the feedback!

← Back to Evidence Rounds